Glaucoma Clinical Trial
Official title:
Evaluation of New Head-mounted Visual Aids Among Patients With Low Vision
Glaucoma, age-related macular degeneration (AMD), retinitis pigmentosa, RP, diabetic retinopathy (DR) are the most common blinding eye diseases in the world. Vision and visual field are often severely impaired, quality of life is reduced, and personal and family burdens are heavy. This kind of low vision people, can use visual AIDS and other instruments for visual rehabilitation training, maximize the function of residual vision, improve the quality of life. Beyes, HOLA, Acesight and OXSIGHT are among the latest eyeglasses devices that are expected to improve the quality of life for people with low vision. This research group intends to recruit advanced patients with primary glaucoma, AMD, RP, DR and other common blinding eye diseases who visited Zhongshan Ophthalmology Center of Sun Yat-sen University from June 2021 to December 2022 to study the changes of visual function and quality of life after wearing this new type of head-worn visual aids, and analyze relevant factors combined with clinical data. To evaluate the effect and influencing factors of the new head-mounted visual AIDS on patients, and provide theoretical basis for subsequent clinical research.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | October 10, 2024 |
Est. primary completion date | August 10, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. age =10 years, able to complete all tests and inspections 2. a definite diagnosis of low vision or blindness: - Criteria for low vision: the best corrected visual acuity of the better eye =0.3, and =0.05 or the visual field of the better eye no greater than 20° in radius around central fixation - Criteria for blindness: the best corrected visual acuity of the better eye <0.05 or the visual field of the better eye no greater than 10° in radius around central fixation 3. Visual acuity, intraocular pressure, and other eye conditions have been stable for more than 6 months. Exclusion Criteria: 1. unable to cooperate with related inspections 2. a history of eye surgery or eye laser within six months 3. serious systemic diseases, such as neurological diseases, cardiovascular diseases, psychological diseases, malignant tumors, etc. 4. pregnant or lactating women 5. those who refuse to sign the informed consent or voluntarily withdraw from the study due to discomfort or other reasons. |
Country | Name | City | State |
---|---|---|---|
China | Zhongshan Ophthalmic Center, Sun Yat-sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Zhongshan Ophthalmic Center, Sun Yat-sen University |
China,
Fontenot JL, Bona MD, Kaleem MA, McLaughlin WM Jr, Morse AR, Schwartz TL, Shepherd JD, Jackson ML; American Academy of Ophthalmology Preferred Practice Pattern Vision Rehabilitation Committee. Vision Rehabilitation Preferred Practice Pattern(R). Ophthalmo — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of changes in the Glaucoma Visual Functioning Questionnaire-40 (GVFQ-40) scores at different time points | The GVFQ-40 consists of 40 items and measures the difficulty of daily activities of glaucoma patients in five domains of functioning (mobility, visual tracking, reading, identification and night vision ). Each item has six answer options, that is, no difficulty (score = 1), mild difficulty (score = 2), moderate difficulty (score = 3), extremely difficult (score = 4), completely unable to complete (score = 5), and do not perform for nonvisual reasons (no score). The GVFQ-40 was administered at baseline and 1 day, 1 week, 4 weeks, and 8 weeks after intervention. | 8 weeks after intervention | |
Primary | Comparison of changes in the National Eye Institute-Visual Function Questionnaire-25 (NEI VFQ-25) scores at different time points | The National Eye Institute-Visual Function Questionnaire-25 (NEI VFQ-25) is a valid and reliable vision-related quality of life (QOL) questionnaire designed for persons who have chronic eye diseases or low vision. It includes 25 items that comprise 11 subscales on different aspects of vision-related functioning and QOL and 1 item on general health. NEI VFQ-25 scores range from 0 to 100, with a higher score representing better functioning. The NEI VFQ-25 was administered at baseline and 1 day, 1 week, 4 weeks, and 8 weeks after intervention. | 8 weeks after intervention | |
Primary | Comparison of changes in the Low Vision Quality-of-Life Questionnaire (LVQOL) scores at different time points | The Low Vision Quality-of-Life Questionnaire (LVQOL) specifically examines the QOL of patients with visual disability. The LVQOL is of the latter type, with the 25 items producing a summed score between 0 and 125 (the higher the score, the higher the quality of life). The 25 items are grouped into 4 subscales: distance vision, mobility and lighting; adjustment; reading and fine work; and daily life activities. As a convenient tool, LVQOL is widely used in clinical settings to evaluate effects of clinical treatment and corresponding strategies of low-vision rehabilitation. The LVQOL was tested at baseline and 1 day, 1 week, 4 weeks, and 8 weeks after intervention. | 8 weeks after intervention | |
Secondary | Comparison of changes in visual acuity at different time points | Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart was used. The examination was performed at baseline and 1 day, 1 week, 4 weeks, and 8 weeks after intervention. | 8 weeks after intervention | |
Secondary | Comparison of changes in contrast sensitivity at different time points | Pelli-Robson Contrast Sensitivity Charts were used. The examination was performed at baseline and 1 day, 1 week, 4 weeks, and 8 weeks after intervention. | 8 weeks after intervention | |
Secondary | Comparison of changes in kinetic visual field at different time points | Kinetic visual field was measured by the automated perimetry. The examination was performed at baseline and 1 day, 1 week, 4 weeks, and 8 weeks after intervention. | 8 weeks after intervention | |
Secondary | Comparison of changes in functional magnetic resonance imaging (MRI) at different time points | The whole brain BOLD and T1 structures were scanned using a MAGNETOM Verio 3 T MR scanner. Structural and functional MRI scans were performed at baseline and at 1 week, 8 weeks, and 6 months after intervention. | 6 months after intervention | |
Secondary | Comparison of changes in mobility test at different time points | A mobility test was performed to evaluate patients' functionality in 2 scenarios: using their presenting distance visual acuity with no aids and using the head-mounted aids. A loop-shaped obstacle course consisting of stationary obstacles from floor to head level was designed for this test. The test was performed at baseline and 1 day, 1 week, 4 weeks, and 8 weeks after intervention. | 8 weeks after intervention | |
Secondary | Comparison of changes in visual scanning test at different time points | A visual scanning test was performed to evaluate patients' functionality in 2 scenarios: using their presenting distance visual acuity with no aids and using the head-mounted aids. Four pictures were designed for this test. Each picture involved seven types of randomly aligned figures and the four patterns of pictures with different alignments were prepared to determine the scores of individuals and the time required to answer. The test was performed at baseline and 1 day, 1 week, 4 weeks, and 8 weeks after intervention. | 8 weeks after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A |